FINWIRES · TerminalLIVE
FINWIRES

$IDXX

7 stories mentioning IDXXUpdated 40d ago

Every FINWIRES story that references IDXX, newest first.

Research

Research Alert: CFRA Keeps Hold Rating On Shares Of Idexx Laboratories, Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our target to $612 from $620, based on 37.3x our 2027 EPS estimate, below IDXX's historical forward P/E averages. We slightly raise our 2026 EPS view to $14.70 from 14.67. We keep our 2027 view at $16.42. IDXX reported a solid Q1, exceeding expectations, with revenue of $1.141B (+11% Y/Y organic) due to strong performance in its Companion Animal Group Diagnostics recurring revenue. However, we see IDXX facing risks in the near term stemming from macroeconomic pressures on consumers that are causing a decline in discretionary wellness-related veterinary visits. This trend poses a financial risk, as IDXX full-year guidance assumes a 1.5% decline in U.S. clinical visits; thus, a further worsening of the economic environment could lead to steeper declines and challenge revenue targets. Additionally, IDXX flagged a minor supply chain disruption in the Middle East, which, while contained, underscores the potential for broader operational risks within global business activities.

$IDXX
Sectors

Sector Update: Health Care Stocks Higher Pre-Bell Tuesday

Health care stocks were higher premarket Tuesday, with the State Street Health Care Select Sector SPDR ETF (XLV) gaining by 0.1% and the iShares Biotechnology ETF (IBB) advancing 0.2%.IDEXX Laboratories (IDXX) shares rose more than 3% pre-bell after the company reported higher Q1 comparable earnings and revenue.Waters (WAT) shares were over 10% higher pre-bell after the company reported higher fiscal Q1 adjusted earnings and revenue.Fresenius Medical Care (FMS) stock was down more than 5% premarket after the company reported lower Q1 earnings and revenue.

$FMS$IBB$IDXX$WAT$XLV
Sectors

Sector Update: Health Care

Health care stocks were higher premarket Tuesday, with the State Street Health Care Select Sector SPDR ETF (XLV) gaining by 0.1% and the iShares Biotechnology ETF (IBB) advancing 0.2%.IDEXX Laboratories (IDXX) shares rose more than 3% pre-bell after the company reported higher Q1 comparable earnings and revenue.

$IBB$IDXX$XLV
Research

Research Alert: Idexx Posts Solid Q1 Fueled By Innovation And Strong Cag Group Performance

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:IDEXX posted strong Q1 results with EPS of $3.47 (+17% Y/Y), beating expectations by $0.06, while revenue reached $1.141B (+14% Y/Y), $30M above consensus. CAG Diagnostics recurring revenue grew 14% Y/Y to $920M, demonstrating resilient demand for core diagnostic solutions. Operating margin expanded 10 bps to 31.8%, supported by strong recurring revenue gains and operational productivity initiatives. International markets showed particular strength with CAG revenue growing 22.7% compared to 11% domestically, highlighting successful global expansion efforts, in our view. The 12% expansion in the global premium instrument installed base and 20% growth in VetLab consumables underscore continued innovation adoption. Management raised the full-year 2026 guidance, reflecting confidence in the business trajectory, in our view: IDXX sees 2026 sales in the range of $4.675B-4.760B vs. prior $4.632B-$4.720B, representing +8.6%-10.6% Y/Y growth and EPS of $14.45-$14.90 vs. prior $14.29-$14.80, reflecting +11%-14% Y/Y.

$IDXX
Commodities

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Tuesday Amid Corporate Earnings Rush

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.4% and the actively traded Invesco QQQ Trust (QQQ) advanced 0.6% in Tuesday's premarket activity amid a rush of corporate earnings.US stock futures were also higher, with S&P 500 Index futures up 0.4%, Dow Jones Industrial Average futures advancing 0.3%, and Nasdaq futures gaining 0.6% before the start of regular trading.International trade data for March will be released at 8:30 am ET, followed by S&P global services data for April at 9:45 am ET.ISM manufacturing data for April, job openings data for March, and new home sales data for March are all due at 10 am ET.Federal Reserve Vice Chair for Supervision Michelle Bowman and Fed Governor Michael Barr are slated to speak on Tuesday.In premarket activity, bitcoin was up by 1.1%. Among cryptocurrency ETFs, the cryptocurrency fund ProShares Bitcoin Strategy ETF (BITO) was 1.3% higher, Ether ETF (EETH) advanced 1%, and Bitcoin & Ether Market Cap Weight ETF (BETH) was flat.Power Play:IndustrialThe State Street Industrial Select Sector SPDR ETF (XLI) advanced 0.3%, while the Vanguard Industrials Index Fund (VIS) rose 1.7%, and the iShares US Industrials ETF (IYJ) was inactive.Sterling Infrastructure's (STRL) stock was up more than 25% before the opening bell after the company overnight reported a stronger-than-expected rise in Q1 earnings and sales, and guided fiscal 2026 sales above analyst expectations.Winners and Losers:ConsumerThe State Street Consumer Staples Select Sector SPDR ETF (XLP) gained 0.01% and the Vanguard Consumer Staples Index Fund ETF Shares (VDC) was up 0.6%. The iShares US Consumer Staples ETF (IYK) was inactive. The State Street Consumer Discretionary Select Sector SPDR ETF (XLY) advanced 0.3%. The VanEck Retail ETF (RTH) was inactive, while the State Street SPDR S&P Retail ETF (XRT) was 0.7% higher.Anheuser-Busch InBev (BUD) shares were up more than 6% pre-bell after the company reported higher fiscal Q1 underlying earnings and revenue.EnergyThe iShares US Energy ETF (IYE) was inactive, while the State Street Energy Select Sector SPDR ETF (XLE) was up by 0.1%.Kosmos Energy (KOS) stock was down more than 1% before the opening bell after the company reported a Q1 adjusted loss versus analysts' expectations of earnings.Health CareThe State Street Health Care Select Sector SPDR ETF (XLV) advanced 0.1%, the Vanguard Health Care Index Fund (VHT) gained 0.5%, while the iShares US Healthcare ETF (IYH) was flat. The iShares Biotechnology ETF (IBB) was 0.2% higher.IDEXX Laboratories (IDXX) stock was up more than 3% premarket after the company reported higher Q1 comparable earnings and revenue.FinancialThe State Street Financial Select Sector SPDR ETF (XLF) advanced 0.4%. Direxion Daily Financial Bull 3X Shares (FAS) was up 0.5%, while its bearish counterpart, Direxion Daily Financial Bear 3X Shares (FAZ), was 0.2% lower.HSBC (HSBC) shares were down more than 3% pre-bell after the company reported lower-than-expected Q1 earnings.TechnologyThe State Street Technology Select Sector SPDR ETF (XLK) gained 0.8%, and the iShares US Technology ETF (IYW) was flat, while the iShares Expanded Tech Sector ETF (IGM) was up 0.3%. Among semiconductor ETFs, the State Street SPDR S&P Semiconductor ETF (XSD) was 1.9% higher, while the iShares Semiconductor ETF (SOXX) rose by 1.4%.Leidos Holdings (LDOS) shares were up more than 2% in Tuesday's premarket activity after the company reported higher Q1 non-GAAP earnings and revenue.CommoditiesFront-month US West Texas Intermediate crude oil retreated by 2.4% to $103.92 per barrel on the New York Mercantile Exchange. Natural gas was down by 1.3% at $2.83 per 1 million British Thermal Units. The United States Oil Fund (USO) fell by 1.1%, while the United States Natural Gas Fund (UNG) was 0.8% lower.Gold futures for May gained by 0.9% to reach $4,573.50 an ounce on the Comex. Silver futures advanced by 0.9% to $74.20 an ounce. SPDR Gold Shares (GLD) was 1% higher, and the iShares Silver Trust (SLV) rose by 1.1%.

Dow JonesNasdaq CompositeS&P 500$BETH$BITO$BUD$EEM$EETH$EXI$FAS$FAZ$GLD$HSBC$IBB$IDXX$IGM$IGV$IPK$IVV$IWM$IYE$IYH$IYJ$IYK$IYW$KOS$LDOS$PMR$QQQ$RTH$SLV$SOXX$SPY$STRL$UNG$USO$VDC$VHT$VIS$XLE$XLF$XLI$XLK$XLP$XLV$XLY$XRT$XSD
Research

Research Alert: CFRA Lowers Rating On Shares Of Idexx Laboratories, Inc. To Hold From Buy

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We cut our target to $620, 37.8x our 2027 EPS estimate, below IDXX's historical forward P/E averages. We reduce our 2026 EPS view to $14.67 from $14.73 and keep our 2027 view at $16.42. We think the company is entering a transitional period marked by leadership change while the uncertainty in the current economic environment may constrain veterinary visits and pet owners' spend. In January 2026, the company announced that Michael Erickson, who has been with IDXX since 2011, will assume the role of President and CEO on May 12, 2026, succeeding the long-tenured CEO Jay Mazelsky, who will move to Executive Chair before retiring in May 2027. While pet owners continue to prioritize their companion animals' health, with pet-care costs rising above inflation in recent years, we think the focus may shift to essential visits only if inflationary pressures persist. The company will host its Q1 analyst call on May 12, when we expect to hear more on the near-term outlook and pet-care cost trends impacting IDXX.

$IDXX
Research

Citigroup Initiates IDEXX Laboratories at Neutral With $650 Price Target

IDEXX Laboratories (IDXX) has an average rating of overweight and mean price target of $758.38, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$IDXX

Track with the FINWIRES app suite